Anna Slager

USPTO Granted Patents = 11 (Patent Applications = 8)

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 1 (Patent Applications = 9)

Average Co-Inventor Count = 4.1

ph-index = 1

Forward Citations = 4(Granted Patents)

Location History:

Landsdale, PA (US) (2022)
Lansdale, PA (US) (2021 - 2024)

Company Filing History:

11 out of 87

Inovio Pharmaceuticals, Inc.

patents

1 out of 2,597

University of Pennsylvania

where one patent can have more than one assignee

Years Active: 2021-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12285473 - Cancer vaccines targeting MUC16 and uses thereof (2025-04-29),

2. 12161706 - Cancer vaccines targeting BORIS and uses thereof (2024-12-10),

3. 12064473 - Cancer vaccines targeting Survivin and uses thereof (2024-08-20),

4. 11986517 - Cancer vaccines targeting mesothelin and uses thereof (2024-05-21),

5. 11865166 - Nucleic acid encoding optimized immunogenic peptide that targets follicle stimulating hormone receptor (2024-01-09),

6. 11744885 - Vaccines for recurrent respiratory papillomatosis and methods of using the same (2023-09-05),

7. 11338029 - Cancer vaccines targeting PRAME and uses thereof (2022-05-24),

8. 11338028 - Cancer vaccines targeting LEMD1 and uses thereof (2022-05-24),

9. 11235044 - Cancer vaccines targeting MUC16 and uses thereof (2022-02-01),

10. 11154602 - Cancer vaccines targeting mesothelin and uses thereof (2021-10-26),

11. 11154601 - Cancer vaccines targeting BORIS and uses thereof (2021-10-26),

Title: **The Innovative Journey of Anna Slager**

Introduction

Anna Slager, an accomplished inventor based in Lansdale, PA, has made significant strides in the field of cancer research. With a remarkable portfolio of 11 patents, her contributions focus on pioneering cancer vaccines that target specific antigens associated with tumor cells.

Latest Patents

Among her latest innovations are two groundbreaking patents which showcase her dedication to developing effective cancer treatments. The first patent involves cancer vaccines targeting MUC16, disclosing nucleic acid molecules that encode a modified consensus MUC16 antigen. This includes vectors, compositions, and vaccines designed to treat subjects with MUC16-expressing tumors, aiming to prevent tumor progression effectively.

The second patent centers around cancer vaccines targeting BORIS, which highlights nucleic acid molecules encoding a synthetic consensus BORIS antigen. This invention emphasizes methods to treat subjects with BORIS-expressing tumors and strategies to prevent their occurrence, marking a significant contribution to the oncology field.

Career Highlights

Anna Slager has built an impressive career at notable institutions such as Inovio Pharmaceuticals, Inc. and the University of Pennsylvania. Her work at these organizations has significantly impacted the development of innovative therapies for cancer treatment, leveraging cutting-edge research to advance her inventions.

Collaborations

Throughout her journey, Anna has collaborated with prominent figures in the research community, including coworkers Jian Yan and Bradley Garman. These partnerships have further enhanced her ability to innovate and contribute to pivotal advancements in cancer therapy.

Conclusion

Anna Slager's dedication and ingenuity exemplify the innovative spirit in the realm of medical research. Her patents not only represent her commitment to cancer treatment but also inspire future generations of inventors and researchers in the medical field. As she continues her groundbreaking work, the impact of her contributions will likely extend far and wide, transforming the landscape of cancer therapies and treatments.

This text is generated by artificial intelligence and may not be accurate.